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MinireviewPolyglutamine Pathogenesis:
Emergence of Unifying Mechanisms
for Huntington’s Disease and Related Disorders
sial. The causative gene with the best-characterized
function is the androgen receptor (AR) of SBMA, which
is a DNA binding, ligand-activated transcription factor.
The literature on the polyglutamine expansion dis-
eases is itself rapidly expanding. Some of the major
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controversies in the field are surveyed in the excellent
Review of Tobin and Signer (2000). Other Reviews in-
clude Merry (2001), Rubinsztein (2002), and Taylor et al.Summary
(2002). There have been many conflicting observations
and hypotheses. Nevertheless, some of the major issuesThe mechanisms of neurodegeneration in the CAG
are becoming resolved, and potential unifying principlesrepeat polyglutamine diseases, including Spinal and
are emerging. Two articles in this issue of Neuron, usingBulbar Muscular Atrophy (SBMA), Huntington’s dis-
models of SBMA, have provided striking in vivo evidenceease (HD), DentatoRubral and PallidoLuysian Atrophy
for some of these principles. One study (Katsuno et al.,(DRPLA), and Spino-Cerebellar Ataxia (SCA), have
2002) reports a new transgenic mouse model generatedbeen controversial. Issues have included the role of
using the androgen receptor with a long polyglutaminepolyglutamine aggregation and possible amyloid for-
repeat. The other (Takeyama et al., 2002) involves Dro-mation, localization in the cell nucleus, and possible
sophila models constructed using several different ARproteolytic processing. Proposed mechanisms have
constructs with expanded repeats. The ability to manip-included activation of caspases or other triggers of
ulate the AR within cells, using agonists and antagonists,apoptosis, mitochondrial or metabolic toxicity, and in-
and then assay transcriptional activation makes SBMAterference with gene transcription. Recent studies us-
an attractive disease to study. Of the other diseases,ing transgenic mouse and Drosophila models have
HD is probably the best studied. This Minireview willhelped resolve some of these issues and raise hopes
highlight these two diseases in order to examine poten-for development of therapeutic targets.
tial unifying principles (see Figures 1 and 2).
One fundamental issue is whether polyglutamine
pathogenesis involves a genetic gain of function or lossNine neurodegenerative disorders are caused by ex-
of function. A genetic gain of function is suggested bypanding CAG repeats coding for polyglutamine (Mar-
the autosomal dominant inheritance of most of the disor-golis and Ross, 2001). They include Spinal and Bulbar
ders (except SBMA, which is X linked and possibly domi-Muscular Atrophy (SBMA), the first to be discovered;
nant at the cellular level) and by most of the results withHuntington’s disease (HD), perhaps the most actively
cell transfection and transgenic and knock-out animalstudied; DentatoRubral and PallidoLuysian Atrophy
experiments. HD in particular has classic pure genetic(DRPLA), which is similar to HD; and several forms of
dominance, with homozygotes having an almost identi-Spino-Cerebellar Ataxia (SCA). Each of the disorders is
cal phenotype to heterozygotes. Nevertheless, somecharacterized by selective neuronal cell death in specific
recent evidence does point to loss of function as a con-regions of the brain. While the exact areas affected in
tributor to pathogenesis. For instance, huntingtin ap-each disease differ, there is considerable overlap, in-
pears to have a neuroprotective function and enhancescluding basal ganglia, brainstem nuclei, cerebellum, and
production of neurotrophic factors, such as brain-spinal motor nuclei (Ross, 1995). Pathology in these
derived neurotrophic factor (Cattaneo et al., 2001). The
regions is characteristic of the polyglutamine disorders,
two current studies find that AR agonists greatly potenti-
and is distinct from other neurodegenerative disorders,
ate the disease phenotype, providing further support for
such as Alzheimer’s disease and Parkinson’s disease. a gain-of-function model. This suggests that neuronal
The genes which cause these disorders have no ho- degeneration in SBMA arises predominantly from a ge-
mology with each other except for the polyglutamine netic gain of function, while the partial androgen insensi-
stretch itself. While the other portions of the proteins tivity seen in some patients would arise from loss of
are likely to exert a modulatory effect, giving rise to receptor function in the periphery.
some of the disease-specific features (Orr, 2001), there A contentious question has been whether pathogene-
are likely to be common pathogenic mechanisms due sis is primarily activated in the cytoplasm or in the cell
to expanded polyglutamine itself. In all of the diseases, nucleus. Studies using manipulation of localization sig-
there is a striking threshold effect of the minimal polyglu- nals in polyglutamine disease proteins, including huntin-
tamine length to cause disease. The exact length is gtin, have concluded that a primary site of cellular toxic-
different in each disease but is generally in the range ity is the nucleus (Saudou et al., 1998; Peters et al., 1999).
of 35 to 45 (except for SCA 6, which may have a different However, other groups have reported a cytoplasmic site
mechanism from the others). All of the mutant proteins of toxicity, including two recent papers. One paper re-
appear to undergo a conformational change and aggre- ports direct mitochondrial toxicity of mutant polyglutam-
gate in cells, forming characteristic inclusion bodies— ine-containing proteins (Panov et al., 2002), which, if
though their role in pathogenesis has been controver- specific, could represent an interesting gain-of-function
mechanism, and a striking coalescence of current ge-
netic methodology with previous hypotheses regarding1Correspondence: caross@jhu.edu
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Figure 1. Model for SBMA Cellular Patho-
genesis
The Androgen Receptor (AR) is cytoplasmic
(and bound to heat shock proteins, not
shown) in its basal state. It consists of several
domains, including an N-terminal transcrip-
tional regulatory region (AF-1), a zinc finger
containing DNA binding region (DBD), a hinge
region with the nuclear localization signal
(NLS), and a C-terminal ligand binding do-
main (LBD). Upon ligand binding, there is a
conformational change which results in ho-
modimerization and dissociation from heat
shock proteins (not shown) and exposure of
the NLS, resulting in nuclear translocation. In
the nucleus, agonist binding results in associ-
ation with androgen response elements
(ARE), leading to the recruitment of coactiva-
tors and activation of gene transcription. By
contrast, antagonist binding results in nu-
clear translocation without targeting to the
androgen response elements or recruitment
of coactivators, and thus, no gene transcrip-
tion. The pathogenesis of SBMA may result
from targeting of the mutant receptor to the
nucleus. The expanded polyglutamine stretch
causes altered conformation of the protein. Upon binding of either agonist or antagonist, the receptor translocates to the nucleus. After
proteolytic cleavage (either in the nucleus or the cytoplasm), the polyglutamine stretch assumes an altered conformation, leading to aggregation
and the formation of intranuclear inclusions. The mutation may confer a gain of a novel toxic property on the AR, such as abnormal interactions
with CBP, leading to loss of neuronal survival signaling.
excitotoxicity or metabolic toxicity. The other recent pa- added to this paradigm. Some AR antagonists, unlike
agonists, induce nuclear translocation of the AR but doper (Gervais et al., 2002) proposes a caspase 8-medi-
ated triggering of apoptotic machinery after a chain of not activate AR-dependent gene transcription. Take-
yama et al. found that androgen antagonists alsoprotein interactions—though this would appear to act
via a loss-of-function mechanism. strongly enhanced toxicity. Furthermore, flies express-
ing only the N-terminal portion of the AR with an ex-The SBMA studies address the issue of nuclear versus
cytoplasmic toxicity. In both the Drosophila and mouse panded repeat and the AR nuclear localization signal
(but no DNA binding region or ligand binding region)models, androgen agonists coordinately induce nuclear
translocation and toxicity. Furthermore, in the Drosoph- also had a severe neurodegenerative phenotype, with
nuclear localization of AR. These results strongly sug-ila paper (Takeyama et al., 2002), an ingenious twist is
Figure 2. Model for HD Cellular Patho-
genesis
Huntingtin is normally predominantly cyto-
plasmic. Its normal function is not well under-
stood but likely involves cytoskeletal function
or vesicle recycling (not shown). It may cycle
to the nucleus and have a normal role in the
regulation of gene transcription, but this is
uncertain. The mutation causes a conforma-
tional change and likely leads to partial un-
folding or abnormal folding of the protein,
which can be corrected by molecular chaper-
ones. Proteolytic cleavage of mutant hunting-
tin takes place. For simplicity, this is shown
as taking place in the cytoplasm, though it
may also take place in the nucleus, and may
involve several steps. The N terminus with
the expanded repeat can assume a  pleated
sheet structure. Toxicity in the cytoplasm
may be caused by mutant full-length protein
or by cleaved protein, and the toxic species
may be soluble monomers or oligomers or,
possibly, insoluble aggregates. Toxicity may
involve inhibition of the proteasome or activa-
tion of caspases directly or via mitochondrial
effects. Cytoplasmic aggregates accumulate
in perinuclear or neuritic regions and are ubiquitinated. The mutant protein translocates to the nucleus, where it forms intranuclear inclusions,
though they are not primarily responsible for toxicity. Nuclear toxicity is believed to be caused by interference with gene transcription.
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gest that the presence of the expanded polyglutamine tamine aggregation in vivo and in vitro is strikingly similar
in the nucleus is sufficient to induce toxicity. They also to the threshold for disease in human patients, as shown
suggest that the “gain” may be a novel function and not by Wanker’s laboratory. However, the neurons with ag-
one related to the AR’s usual action to activate gene gregates are not necessarily the neurons most likely to
transcription. die, and polyglutamine aggregation and cell toxicity can
What might be the molecular mechanisms of polyglu- be experimentally dissociated both in vitro and in vivo.
tamine toxicity in the nucleus? A logical candidate would Thus, the relationship between aggregation and toxic-
be interference with gene transcription. Several recent ity is currently unknown (See Figure 1 of Tobin and
studies have suggested abnormal interactions with nu- Signer, 2000). The recent study of Dunah et al. (2002)
clear coactivator or corepressor molecules, including proposed that interference with gene transcription and
p53, CBP, Sp1, and TAF130 (Steffan et al., 2000; cell toxicity is caused by soluble monomeric polygluta-
McCampbell et al., 2000; Nucifora et al., 2001; Dunah mine species. By contrast, the studies in which mutant
et al., 2002). The details of the molecular interactions in polyglutamine is proposed to interact with short polyglu-
the different studies differ. In some of them (Steffan et tamine stretches present in CBP suggest an interaction
al., 2000; Dunah et al., 2002), interactions take place in some way related to polyglutamine aggregation, and
between the normal polyglutamine protein and the can- CBP has been detected in polyglutamine containing in-
didate transcription factors and are altered by the clusions. However, it is also possible that abnormal
expansion mutation. For instance, in the Dunah et al. polyglutamine interactions could involve monomeric
(2002) study, both normal and mutant huntingtin interact protein, causing an altered conformation of monomeric
with Sp1 and TAF130 and inhibit transcription, but the CBP, leading it to be degraded by the proteasome or
interaction of mutant huntingtin is stronger. Data from other cellular processes. One interesting twist on the
post-mortem HD brain material support the involve- polyglutamine interaction hypothesis is that the ex-
ment of these molecules, beginning very early in the panded polyglutamine in mutant huntingtin could inter-
disease course. However, in this model, higher concen- act with the normal polyglutamine in the huntingtin ex-
trations of normal huntingtin might be expected to have pressed via the other allele, potentially leading to partial
similar effects on Sp1 and TAF130 as mutant huntingtin, inactivation of normal huntingtin. This would be a domi-
but, in many previous cell and mouse studies, expres- nant-negative interaction, which could mediate a loss
sion of normal huntingtin generally does not cause sig- of huntingtin function.
nificant toxicity. When considering the issue of aggregation, it may be
In a different kind of mechanism, originally proposed too simplistic to limit the models for the postulated toxic
by Perutz and supported by data from the labs of Hous- species to either soluble monomers or insoluble fibrilar
man, Paulson, and others, mutant polyglutamine assumes aggregates. Protein aggregation and fiber formation
an altered conformation and binds to short polygluta- leading to amyloid is a complex biochemical process and
mine stretches normally present in many transcription is likely to have a number of intermediate stages, including
factors and transcriptional coactivators, such as Cyclic oligomeric species, and small nascent fibrils, termed “pro-
Adenosine Monophosphate Response Element Binding tofibrils.” Such intermediates have been reported for
Protein (CBP). This polyglutamine interaction is postu- huntingtin (Poirier et al., 2002). The AR transgenic mouse
lated to alter CBP’s structure. Cell transfection studies study (Katsuno et al., 2002) demonstrated that nuclear
have shown that this effect can remove CBP from its label for the AR which appears diffuse at the light micro-
normal site of survival-promoting action within cells, scope level consists of small “microaggregates” at the
causing toxicity (McCampbell et al., 2000; Nucifora et electron microscope level. A mechanism involving ag-
al., 2001). This is only seen with the mutant protein, gregation intermediates would be consistent with recent
consistent with the idea of a gain of a novel function. studies of Parkinson’s and Alzheimer’s diseases and
However, at present, in vivo support for this mechanism
thus has the attractive feature that it could be a general
is sparse.
mechanism for protein misfolding neurodegenerative
Other interactions could also take place in the nu-
diseases (reviewed in Taylor et al., 2002). It is possiblecleus. Another idea is that the abnormal polyglutamine
that several different species—monomer, soluble inter-proteins are targeted for the proteasome but cannot be
mediate, and insoluble aggregate—could all have dif-digested and thus inhibit proteasome activity, poten-
fering deleterious effects on cell function.tially resulting in toxicity. Cell transfection data support
One final question, which remains highly contentious,such a mechanism for mutant huntingtin (Bence et al.,
is the possible role of proteolytic cleavage in polyglu-2001). The assay used in this study could show loss of
tamine pathogenesis. A consistent observation hascytoplasmic proteasome activity, but proteasomes are
been that antibodies to the N terminus of huntingtin, butpresent in both the cytoplasm and the nucleus. Also in
not antibodies to epitopes in the middle of the proteinits favor, this is another mechanism involving a gain of
or at the C terminus, recognize the intranuclear inclu-a novel function.
sions in HD. A number of studies have suggested aAnother controversial issue involves the possible rela-
role for proteolytic cleavage of polyglutamine proteinstion between polyglutamine toxicity and the formation
(Ellerby et al., 1999; Li et al., 2000; Toneff et al., 2002).of polyglutamine aggregates and inclusions. Expanded
The fact that many of the polyglutamine proteins, includ-polyglutamine aggregates both in vitro and in vivo and
ing the androgen receptor (Ellerby et al., 1999), can beforms characteristic inclusion bodies. The aggregates
cleaved by caspase enzymes has suggested that cas-have many of the characteristics of amyloid and are
pase cleavage might be involved. However, other stud-composed of fibers with  sheet structure, like the amy-
loid of Alzheimer’s disease. The threshold for polyglu- ies have equally strongly argued that full-length proteins
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Ellerby, L.M., Hackam, A.S., Propp, S.S., Ellerby, H.M., Rabizadeh,are the most relevant species (Dyer and McMurray,
S., Cashman, N.R., Trifiro, M.A., Pinsky, L., Wellington, C.L.,2001; Wheeler et al., 2000).
Salvesen, G.S., et al. (1999). J. Neurochem. 72, 185–195.The two recent studies of the AR provide striking cor-
Gervais, F.G., Singaraja, R., Xanthoudakis, S., Gutekunst, C.A., Lea-relative evidence for the existence of a proteolytic frag-
vitt, B.R., Metzler, M., Hackam, A.S., Tam, J., Vaillancourt, J.P.,
ment of the AR. In the mouse study, truncated fragments Houtzager, V., et al. (2002). Nat. Cell Biol. 4, 95–105.
of the AR were observed, though the relation to toxicity Katsuno, M., Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H.,
was not assessed. In the Drosophila study, truncated Sang, C., Kobayashi, Y., Doyu, M., and Sobue, G. (2002). Neuron
fragments containing the polyglutamine expansion were 35, this issue, 843–854.
also observed. An additional model generated using a Li, H., Li, S.H., Johnston, H., Shelbourne, P.F., and Li, X.J. (2000).
Nat. Genet. 25, 385–389.truncated fragment with the expanded repeat showed
enhanced toxicity. Lunkes, A., Lindenberg, K.S., Ben-Hayem, L., Weber, C., Devys, D.,
Landwehrmeyer, G.B., Mandel, J.-L., and Trottier, Y. (2002). Mol.Recent data have provided additional evidence for
Cell, 10, 259–269.the cleavage of huntingtin and considerably clarified its
Margolis, R.L., and Ross, C.A. (2001). Trends Mol. Med. 7, 479–482.nature (Lunkes et al., 2002). In both a stable inducible
McCampbell, A., Taylor, J.P., Taye, A.A., Robitschek, J., Li, M., Wal-cell model of HD and in material from HD post-mortem
cott, J., Merry, D., Chai, Y., Paulson, H., Sobue, G., and Fischbeck,brains, there was evidence for several cleavage events,
K.H. (2000). Hum. Mol. Genet. 9, 2197–2202.generating fragment sizes of mutant huntingtin smaller
Merry, D.E. (2001). Brain Res. Bull. 56, 203–207.than would be predicted by caspase cleavage. In the
Nucifora, F.C., Jr., Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K.,cell model, it could be shown that this cleavage was not
Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L., et
mediated by the proteasome, as proteasome inhibition al. (2001). Science 291, 2423–2428.
actually increased the amount of the fragment. Cell
Orr, H.T. (2001). Genes Dev. 15, 925–932.
transfection and inhibitor studies indicated that the most
Panov, A., Gutekunst, C.-A., Leavitt, B.R., Hayden, M.R., Burke, J.R.,
relevant fragment was generated by aspartic endopepti- Strittmatter, W.J., and Greenamyre, J.T. (2002). Nat. Neurosci. 5,
dases, though their nature was not identified. These 731–736.
studies are still correlative, and the relation of this cleav- Peters, M.F., Nucifora, F.C., Jr., Kushi, J., Seaman, H.C., Cooper,
age to toxicity has not yet been reported. If proteolytic J.K., Herring, W.J., Dawson, V.L., Dawson, T.M., and Ross, C.A.
(1999). Mol. Cell. Neurosci. 14, 121–128.cleavage could be established as a central pathogenic
event, it might be an excellent therapeutic target, since Poirier, M.A., Li, H., Macosko, J., Cai, S., Amzel, M., and Ross, C.A.
(2002). J. Biol. Chem., in press.pharmacologic inhibition of proteolytic enzymes may be
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Cell 95, 55–66.still many uncertainties. Some unifying themes do ap-
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evidence for the gain-of-function hypothesis and the this issue, 855–864.
idea that nuclear events are central to pathogenesis,
Taylor, J.P., Hardy, J., and Fischbeck, K.H. (2002). Science 296,
though with possible contributions from loss-of-function 1991–1995.
and cytoplasmic toxicity. Roles for gene transcription, Tobin, A.J., and Signer, E.R. (2000). Trends Cell Biol. 10, 531–536.
intermediates in an aggregation pathway as toxic spe- Toneff, T., Mende-Mueller, L., Wu, Y., Hwang, S.R., Bundey, R.,
cies, and proteolytic cleavage are intriguing but not yet Thompson, L.M., Chesselet, M.F., and Hook, V. (2002). J. Neuro-
proved. While the field has not yet resolved all of the chem. 82, 84–92.
controversies, progress toward identifying key toxic Wheeler, V.C., White, J.K., Gutekunst, C.A., Vrbanac, V., Weaver,
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Genet. 9, 503–13.different diseases are each likely to have their own addi-
tional twists. Answering some of these questions may
help elucidate pathogenic mechanisms relevant to other
neurodegenerative diseases, such as Alzheimer’s dis-
ease and Parkinson’s disease, and will provide targets
for therapeutic intervention.
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